CMTM1: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Target Name: CMTM1

NCBI ID: G113540

CMTM1

CMTM1: A Potential Drug Target and Biomarker for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood cells. It is a potentially curable disease, but despite advances in treatment, the survival rate remains high. The treatment options for CML patients are limited and often have significant side effects. Therefore, there is a need for new treatments that can be effective and have fewer side effects.

One potential drug target for CML is CMTM1, a member of the Chemokine-like factor superfamily. CMTM1 is a transmembrane protein that is expressed in various tissues and cells, including the bone marrow, spleen, and lymphoid organs. It has been shown to play a role in the development and progression of CML.

CMTM1 functions as a receptor for the chemokine interleukin-3 (IL-3), which is a cytokine that plays a critical role in the development and maintenance of immune cells. IL-3 has been shown to promote the proliferation and survival of various types of cancer cells, including leukemia cells. Therefore, CMTM1 has been shown to contribute to the development and progression of CML.

In addition to its role in the development of CML, CMTM1 has also been shown to be a potential biomarker for this disease. The presence of CMTM1 in the blood cells of CML patients has been shown to be associated with the disease severity and the response to treatment.

CMTM1 has also been shown to play a role in the regulation of cellular processes that are important for the survival of cancer cells. For example, it has been shown to regulate the expression of genes involved in cell adhesion, migration, and invasion. This suggests that CMTM1 may be a useful target for drugs that can inhibit these processes in cancer cells.

In conclusion, CMTM1 is a potential drug target and biomarker for CML. Further research is needed to understand the full role of CMTM1 in the development and progression of this disease and to identify effective treatments that can be used to target it.

Protein Name: CKLF Like MARVEL Transmembrane Domain Containing 1

The "CMTM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMTM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets